A Place for Hope

Our immune systems are very careful to fight against dangers such as infections without fighting normal, healthy parts of our bodies.  When it comes to cancer, our immune systems will often start to fight the tumor, but the brakes on the immune response may make the anti-tumor response ineffective.  PD-1 antibodies take the brakes off of the immune response against melanoma, and the results have been dramatic in some patients.  In preliminary studies, up to half of patients treated with PD-1 antibodies showed subtantial improvements in their melanoma, and these improvements can last for years rather than months.  Here at UCSF, we have several clinical trials of PD-1 antibodies open now, a others that will open soon.  These include:

For patients treated previously with ipilimumab:

  • A randomized phase 3 trial of nivolumab versus chemotherapy
  • A randomized phase 3 trial of MK3475 versus chemotherapy with crossover

For patients with no prior exposure to ipilimumab:

  • A randomized phase 3 trial of MK3475 versus ipilimumab
  • A randomized phase 3 trial of nivolumab versus ipilimumab versus both

Contact us for more information regarding these trials and upcoming studies.

Contact:  Dr. Adil Daud, adaud@medicine.ucsf.edu